| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Hydroxy-PP targets two distinct enzymes: carbonyl reductase 1 (CBR1) and the cytoplasmic tyrosine kinase Fyn. CBR1 is a member of the short-chain dehydrogenase/reductase (SDR) family that catalyzes the reduction of carbonyl-containing compounds, including many drugs and endogenous substrates. CBR1 plays a role in the metabolism of chemotherapeutic agents such as anthracyclines and in the biosynthesis of prostaglandins and other lipid mediators. Fyn is a Src family non-receptor tyrosine kinase that is involved in cell signaling pathways regulating proliferation, migration, adhesion, and survival. Fyn has been implicated in cancer progression, neuroinflammation, and synaptic plasticity. Hydroxy-PP inhibits CBR1 with an IC50 of 0.78 μM and Fyn with an IC50 of 5 nM, indicating potent activity against both targets. The compound's dual inhibitory profile makes it useful for studying the interplay between these two enzymes in various pathological conditions.
|
|---|---|
| ln Vitro |
In vitro, Hydroxy-PP demonstrates potent inhibitory activity against both CBR1 (IC50 = 0.78 μM) and Fyn (IC50 = 5 nM). The compound's activity can be measured in enzyme assays using recombinant CBR1 or Fyn and appropriate substrates. For CBR1, typical substrates include daunorubicin or other carbonyl-containing compounds, and enzyme activity is measured by monitoring the reduction of the substrate using spectrophotometric or fluorometric methods. For Fyn, kinase activity is measured using peptide substrates and ATP, with phosphorylation detected by radioactive or fluorescence-based methods. The compound's potent inhibition of both enzymes suggests that it can effectively modulate their activities in cell-based and in vivo studies. However, specific cell-based and in vivo data beyond the IC50 values have not been extensively reported in the available literature. The compound is used primarily as a research tool for studying the roles of CBR1 and Fyn.
|
| ln Vivo |
In vivo activity of Hydroxy-PP has not been extensively reported in the available literature. As a dual inhibitor of CBR1 and Fyn, the compound would be expected to have effects on pathways regulated by these enzymes, including drug metabolism (CBR1) and cell signaling (Fyn). Potential applications could include studies of cancer (where Fyn is involved in tumor progression), neuroinflammation (where both CBR1 and Fyn may play roles), and other diseases. However, specific animal model studies, dosing regimens, and quantitative outcomes have not been reported. The compound's ability to inhibit both targets with high potency suggests that it could be a valuable tool for in vivo studies, but further research would be required to characterize its efficacy, safety, and pharmacokinetic properties in animal models.
|
| Enzyme Assay |
In vitro enzyme assay protocols for Hydroxy-PP would typically involve measuring its inhibition of CBR1 and Fyn activities using appropriate substrates and detection methods. For CBR1 inhibition, a standard protocol would involve incubating recombinant human CBR1 with varying concentrations of Hydroxy-PP (typically 0.1 nM to 10 μM) and a substrate such as daunorubicin or 4-benzoylpyridine in assay buffer (e.g., sodium phosphate, pH 6.5, with NADPH) at 37°C for a defined period (e.g., 30-60 minutes). The reaction is terminated, and the reduction of the substrate is measured spectrophotometrically (e.g., absorbance at 340 nm for NADPH consumption) or fluorometrically. IC50 values are determined from concentration-response curves. For Fyn inhibition, a standard protocol would involve incubating recombinant human Fyn kinase with varying concentrations of Hydroxy-PP, ATP, and a peptide substrate (e.g., poly(Glu,Tyr) or a specific Fyn substrate peptide) in kinase assay buffer at 30°C for 30-60 minutes. Phosphorylation is detected using methods such as 33P-ATP incorporation, TR-FRET, or ADP-Glo luminescence. IC50 values are determined from concentration-response curves.
|
| Cell Assay |
In vitro cell-based assay protocols for Hydroxy-PP would typically involve assessing its effects on CBR1 and Fyn activities in cultured cells. A standard protocol for assessing CBR1 inhibition in cells would involve treating cells with varying concentrations of Hydroxy-PP (typically 0.1 nM to 10 μM) for a defined period (e.g., 1-24 hours), then adding a CBR1 substrate such as daunorubicin and measuring its metabolism by HPLC or by monitoring the fluorescence of the reduced product. For Fyn inhibition, cells are treated with Hydroxy-PP, and Fyn activity is assessed by immunoprecipitation of Fyn followed by in vitro kinase assays using a substrate and 33P-ATP, or by Western blot analysis of Fyn phosphorylation and downstream signaling targets (e.g., FAK, paxillin). Cell viability should be assessed using MTT or similar assays to ensure that observed effects are not due to cytotoxicity. Appropriate controls include vehicle-treated cells and cells treated with selective CBR1 or Fyn inhibitors.
|
| Animal Protocol |
In vivo animal experimental protocols for Hydroxy-PP have not been extensively reported in the literature. Based on its mechanism as a dual CBR1 and Fyn inhibitor, potential studies might involve administering the compound to animal models of cancer or neuroinflammation. A hypothetical protocol for studying its anti-tumor effects would involve implanting tumor cells (e.g., xenograft models) subcutaneously in immunodeficient mice, allowing tumors to reach a certain size, and then administering Hydroxy-PP via oral gavage or intraperitoneal injection at doses determined from preliminary pharmacokinetic and tolerability studies. Treatment would typically be administered daily for 2-4 weeks. Endpoints would include tumor volume measurement, tumor weight at necropsy, assessment of Fyn phosphorylation and downstream signaling in tumor tissues, and assessment of CBR1 activity. For neuroinflammation studies, the compound could be administered in models of neurodegenerative diseases or brain injury. However, specific published protocols are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Hydroxy-PP have not been characterized in published studies. The compound has a molecular weight of 283.33 and a structure that includes a hydroxy group and multiple nitrogen atoms, suggesting moderate lipophilicity and potential for oral bioavailability. Specific PK parameters such as half-life, Cmax, AUC, bioavailability, volume of distribution, and clearance have not been reported. The compound's metabolism, protein binding, and routes of elimination remain uncharacterized. Further pharmacokinetic studies would be required to understand its absorption, distribution, metabolism, and excretion profile. The compound should be stored under recommended conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for Hydroxy-PP are limited, as the compound is intended for research use only and has not undergone systematic toxicity testing. No acute toxicity (LD50), subchronic toxicity, genotoxicity, or reproductive toxicity studies have been reported specifically for this compound. As with all research chemicals, appropriate safety precautions should be taken when handling the compound, including working in a fume hood, wearing appropriate personal protective equipment, and avoiding inhalation, ingestion, or skin contact. The compound is not intended for human use. Researchers should consult the material safety data sheet (MSDS) for specific safety information and handling recommendations.
|
| References | |
| Additional Infomation |
Hydroxy-PP is a research-grade compound that functions as a potent inhibitor of carbonyl reductase 1 (CBR1) with an IC50 of 0.78 μM and of the cytoplasmic tyrosine kinase Fyn with an IC50 of 5 nM. It is used as a research tool to study the roles of CBR1 and Fyn in various biological processes, including cancer, inflammation, and neurodegenerative diseases. The compound has not entered clinical trials and is not approved for any therapeutic indication. Its mechanism of action involves inhibition of CBR1, which modulates the metabolism of carbonyl-containing compounds, and inhibition of Fyn, which modulates cell signaling pathways involved in proliferation, migration, and survival. Hydroxy-PP is available exclusively for research purposes and is not intended for diagnostic, therapeutic, or human applications.
|
| Molecular Formula |
C15H17N5O
|
|---|---|
| Molecular Weight |
283.33
|
| Exact Mass |
283.143
|
| CAS # |
833481-60-0
|
| PubChem CID |
657095
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.117
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
372
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1(O)=CC=CC(C2C3=C(N)N=CN=C3N(C(C)(C)C)N=2)=C1
|
| InChi Key |
CPLGZXQPPYRNRC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H17N5O/c1-15(2,3)20-14-11(13(16)17-8-18-14)12(19-20)9-5-4-6-10(21)7-9/h4-8,21H,1-3H3,(H2,16,17,18)
|
| Chemical Name |
3-(4-amino-1-tert-butylpyrazolo[3,4-d]pyrimidin-3-yl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :≥ 110 mg/mL (~388.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (9.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 27.5 mg/mL clear DMSO stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (9.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one),clear solution. For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 27.5 mg/mL clear DMSO stock solution and add it to 900 μL of 20% SBE-β-CD saline solution and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5295 mL | 17.6473 mL | 35.2945 mL | |
| 5 mM | 0.7059 mL | 3.5295 mL | 7.0589 mL | |
| 10 mM | 0.3529 mL | 1.7647 mL | 3.5295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
